Loading data for XENE — first visit, this takes a few seconds.

알림

Xenon Pharmaceuticals Inc... (XENE)

NasdaqGM: XENE · 실시간 가격 · USD

60.42

-0.14 (-0.23%)

종가 기준: Aug 28, 2026, 8:00 PM

59.99

+0.00%

애프터마켓: 4:20 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

-0.23% (1D)

데이터 없음

매수호가	47.27
시가총액	5.81B
매출 (ttm)	n/a
순이익 (ttm)	-409.2M
	0.63
	-4.74
	n/a
	-12.33
P/B (ttm)	4.67
P/S (ttm)	n/a
실적 발표일	Nov 2, 2026

매도호가	82.15
거래량	418,012
평균 거래량 (20일)	1,309,563
시가	61.01
전일 종가	60.56
일중 범위	60.27 - 61.67
52주 범위	35.60 - 72.66
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

XENE 소개

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, a...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Nov 5, 2014

직원 수 358

상장 거래소 NasdaqGM

티커 XENE

웹사이트 https://www.xenon-pharma.com

전체 기업 정보

재무 실적

2025년 Xenon Pharmaceuticals의 매출은 7.5M로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -345.91M로, 47.62% 증가했습니다.

재무제표

어닝 서프라이즈

Xenon Pharmaceuticals가 Aug 6, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 -100.00% 전년 대비 감소.
EPS -1.11 예상치 상회 0.05, 및 -3.74% 전년 대비 감소.

다음 실적 발표

Xenon Pharmaceuticals Inc.의 실적 발표 예정일은 Nov 2, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

2주 전 · Motley Fool

Xenon Pharmaceuticals (XENE) Q2 2026 Earnings Call Transcript

Azetukalner advances toward FDA submission as pain pipeline matures.

3주 전 · MarketBeat

Xenon Pharmaceuticals Q2 Earnings Call Highlights

10x Genomics reported second-quarter revenue of $151 million, including $1.6 million in license and royalty revenue tied to its settlement with Takara Bio. Excluding non-recurring settlement revenue i...

3주 전 · MT Newswires

Xenon Pharmaceuticals' Azetukalner NDA Filing Remains on Track After FDA Meeting, RBC Says

Xenon Pharmaceuticals' (XENE) recent pre-NDA meeting with the FDA for azetukalner appeared construct

3주 전 · Zacks

XENE's Q2 Loss Narrower Than Expected, Sales Nil, Pipeline in Focus

Xenon posts a narrower-than-expected Q2 loss as azetukalner advances toward a planned FDA filing, while its cash runway is expected to support operations into 2029.

3주 전 · GuruFocus.com

Xenon Pharmaceuticals Inc (XENE) (Q2 2026) Earnings Call Highlights: Advancing Azetukalner ...

Xenon Pharmaceuticals Inc (XENE) reports robust pipeline progress and $1.2 billion in cash, funding operations into 2029 as it prepares for regulatory submission.

2 페이지 중 1

Xenon Pharmaceuticals Inc... (XENE)